Alternatives to Immitra Bio
Immitra Bio is a Biotechnology tool: scalable, one-time curative in-vivo gene editing therapies. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to Immitra Bio
- Website
CRISPR Therapeutics64BiotechnologyZug, Switzerland$547.0MBiotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
- Website
Editas Medicine42BiotechCambridge, United States$210.0MA clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
- Website
Intellia Therapeutics40BiotechCambridge, United States$310.0MA clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
Mammoth Biosciences63BiotechnologyBrisbane, United States$460.0MBiotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.
- Website
Epicrispr Biotechnologies62BiotechnologySouth San Francisco, United States$90.0MEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
- Website
Pixelgen Technologies62BiotechnologyStockholm, Sweden$43.5MA life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
LifeMine Therapeutics Inc.60BiotechnologyWatertown, United States$543.0MClinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
Network Bio60BiotechnologyPalo Alto, United States$100.0MLeveraging AI and a massive patient tissue dataset to accelerate drug discovery and advance precision medicine.
- Website
Quartzy60BiotechnologyHayward, USA$40.0MA vertically-integrated procurement platform for the life sciences industry.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Celerion59BiotechnologyLincoln, USA$45.0MA global leader in clinical pharmacology and bioanalytical sciences.
- Website
Freenome59BiotechnologySouth San Francisco, USA$570.0MFreenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website
Janux Therapeutics57BiotechnologySan Diego, USA$181.0MA clinical-stage biopharmaceutical company developing novel immunotherapies.
- Website LŌLōkahi Therapeutics57BiotechnologyLa Jolla, USA$63.0M
A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.
Showing the 20 closest matches. See the rest on the Immitra Bio profile.